On February 24, 2026, Novakand Pharma AB (publ) ("Novakand" or "the Company") announced that Nasdaq has rejected Novakand's application for approval of continued listing on the First North Growth Mark ...
Modus Therapeutics Holding AB ("Modus Therapeutics") hereby publishes year-end report for 2025. The report is available on the company's website ( ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results